ISDA

Entry Detail

PDB ID:

3FLI

Keywords:

TRANSCRIPTION

Title:

Discovery of XL335, a Highly Potent, Selective and Orally-Active Agonist of the Farnesoid X Receptor (FXR)

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2008-12-18

Release Date:

2009-12-22

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Free:

0.24

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Bile acid receptor
Chain IDs:A
Chain Length:231
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q96RI1 Pfam ID:PF00104

Ligand Molecules

33Y

Primary Citation

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).

Flatt, B, Martin, R, Wang, T.L, Mahaney, P, Murphy, B, Gu, X.H, Foster, P, Li, J, Pircher, P, Petrowski, M, Schulman, I, Westin, S, Wrobel, J, Yan, G, Bischoff, E, Daige, C, Mohan, R.Show

J.Med.Chem. 52 904 907 (2009)

PMID: 19159286 DOI: 10.1021/jm8014124

Abstact

Azepino[4,5-b]indoles have been identified as potent agonists of the farnesoid X receptor (FXR). In vitro and in vivo optimization has led to the discovery of 6m (XL335, WAY-362450) as a potent, selective, and orally bioavailable FXR agonist (EC(50) = 4 nM, Eff = 149%). Oral administration of 6m to LDLR(-/-) mice results in lowering of cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions.

Legend

Protein

Chemical

Disease

Primary Citation of related structures